Check out our most popular compounded medications! Get Started
Morphine Sulfate 130 mg Slow Release Capsules are formulated with Methocel E4M, a controlled-release polymer. This design allows for the gradual release of the active ingredient over an extended period, providing sustained therapeutic effects. This formulation is used to treat various types of pain including chronic, cancer, postoperative, neuropathic, and arthritis pain. The slow release mechanism reduces dosing frequency and improves patient compliance for medications requiring a controlled and prolonged release profile.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Morphine Sulfate 130 mg Slow Release Capsules are a potent, long-acting opioid analgesic specifically designed for the management of moderate to severe chronic pain. This unique formulation incorporates Methocel E4M, a type of controlled-release polymer, which ensures a gradual and consistent release of the active ingredient, morphine sulfate, over an extended period of time. This slow-release mechanism offers sustained therapeutic effects, thereby reducing the frequency of dosing and enhancing patient compliance, particularly for medications that necessitate a controlled and prolonged release profile.
It is crucial to understand that this formulation is not intended for the treatment of acute pain. Its use should be strictly limited to chronic pain management under the supervision of a healthcare professional. The slow-release mechanism of this formulation may not provide immediate relief in cases of sudden, acute pain episodes.
Patients should be cognizant of potential side effects, which may include drowsiness, dizziness, among others. It is imperative to adhere to the prescribed dosage and schedule, as this medication can be habit-forming. Prolonged use beyond the prescribed duration is strongly discouraged due to the risk of dependency and addiction.
Healthcare providers prescribing Morphine Sulfate 130 mg Slow Release Capsules should be vigilant in monitoring patients for signs of misuse or abuse. Dose adjustments may be necessary based on the patient's response and tolerance to the medication. It is essential to maintain open communication with patients about their pain levels and any side effects they may be experiencing.
If you have any queries or concerns regarding Morphine Sulfate 130 mg Slow Release Capsules, please do not hesitate to contact us at Bayview Pharmacy. Our team of compounding pharmacists is equipped with the knowledge and expertise to assist you with your medication needs.
Morphine Sulfate 130 mg Slow Release Capsules are a potent analgesic medication indicated for the management of moderate to severe pain. This particular formulation utilizes Methocel E4M, a type of controlled-release polymer, which is designed to gradually release the encapsulated medication over an extended period of time. This slow-release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications that require a controlled and prolonged release profile.
It is crucial to note that Morphine Sulfate 130 mg Slow Release Capsules should not be used in patients with a known hypersensitivity to morphine or other opioids, or in patients with significant respiratory depression. Regular monitoring for signs of respiratory depression, sedation, and hypotension is necessary when using this medication. Additionally, patients should be observed for signs of opioid addiction, abuse, and misuse.
Special caution should be exercised when administering Morphine Sulfate 130 mg Slow Release Capsules to patients with renal or hepatic impairment, as well as in elderly patients, due to the potential for increased sensitivity to the drug's effects. Patients are strongly advised to avoid alcohol and other CNS depressants while taking this medication, as it may increase the risk of adverse effects. Furthermore, patients should refrain from activities requiring mental alertness, such as driving or operating machinery, until they fully understand how this medication affects them.
Always consult with a healthcare professional for any questions or concerns regarding this medication.
Morphine Sulfate 130 mg Slow Release Capsules are a potent, extended-release opioid medication designed to manage moderate to severe pain. These capsules are formulated with Methocel E4M, a type of controlled-release polymer, which ensures the gradual release of the encapsulated medication over an extended period. This slow-release mechanism provides a consistent level of pain relief, reduces the frequency of dosing, and enhances patient compliance, particularly for medications requiring a controlled and prolonged release profile.
The capsules are administered orally, typically once a day, and should be consumed with food. It is crucial to adhere to the prescribed dosage and frequency set by your healthcare provider. Overdosing or underdosing, as well as taking the medication more frequently than advised, can lead to adverse effects or diminished efficacy.
Morphine Sulfate 130 mg Slow Release Capsules are versatile in their application, providing relief from chronic pain, cancer pain, post-operative pain, and pain associated with end-stage renal disease, sickle cell anemia, among other conditions.
While effective, Morphine Sulfate 130 mg Slow Release Capsules may cause side effects such as nausea, vomiting, constipation, dizziness, drowsiness, and confusion. More severe side effects can include respiratory depression, which can be life-threatening. It is essential to communicate with your healthcare provider about any side effects experienced while on this medication.
If you have any queries or concerns regarding Morphine Sulfate 130 mg Slow Release Capsules, please do not hesitate to reach out. Our team of compounding pharmacists at Bayview Pharmacy is here to assist you.
Morphine Sulfate 130 mg Slow Release Capsules is a medication formulated with Methocel E4M, a type of controlled-release polymer. This formulation is designed to gradually release the encapsulated medication over an extended period of time.
The controlled-release polymer, Methocel E4M, is designed to release the active ingredient gradually over an extended period of time. This offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance for medications requiring a controlled and prolonged release profile.
The benefits of using this medication include sustained therapeutic effects due to the gradual release of the active ingredient, reduced dosing frequency, and improved patient compliance due to the controlled and prolonged release profile.
The slow release mechanism works by gradually releasing the encapsulated medication over an extended period of time. This is achieved through the use of a controlled-release polymer, Methocel E4M.
Methocel E4M is a type of controlled-release polymer used in the formulation of certain medications. It is designed to gradually release the active ingredient over an extended period of time.
The frequency of dosing will depend on your doctor's instructions. However, the formulation is designed to reduce the frequency of dosing due to its controlled and prolonged release profile.
'Improved patient compliance' refers to the increased likelihood of patients correctly following their medication regimen. This is often achieved through reduced dosing frequency and sustained therapeutic effects, as is the case with Morphine Sulfate 130 mg Slow Release Capsules.
No, breaking or crushing the capsules can interfere with the controlled-release mechanism and may lead to a rapid release and absorption of a potentially fatal dose of morphine.
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Do not double the dose to catch up.
Common side effects may include drowsiness, dizziness, constipation, or sweating. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
